Replies to post #526 on Beleave, Inc (BLEVF)

[Nelly 15]

Over the last year, the Company has made a series of announcements, acquisitions, and investments to prepare for the anticipated increased demand in the Canadian and International marketplaces. Some highlights include:
-- May 10, 2018: Beleave acquires Medi-Green, a leading network of medical cannabis clinics with existing and additional planned locations across Ontario and Quebec, becoming more closely involved in the patient experience.
-- June 21, 2018: Beleave acquires 51% of Procannmed S.A.S., a privately held company that is fully licensed for the cultivation, production, extraction and distribution of THC and CBD medical cannabis in Colombia.
-- July 19, 2018: Beleave acquires Seven Oaks as its recreational brand, which has a proven track record of working collaboratively to secure wholesale and distribution agreements with retailers across Canada, in pursuance of its recreational distribution and sales strategy.
-- September 6, 2018: Beleave announces plans to acquire 250,000 square feet of greenhouse space and 85 acres of land in London, Ontario to cultivate and harvest cannabis for distribution and sale in Canada.
-- September 20, 2018: Beleave enters into partnership with Kannavis Biotech Corp. to invest, build, and operate 867,000 square feet of indoor growing space in British Columbia.

[Nelly 15]

Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") is pleased to announce that it has signed an agreement with Canymed GmbH ("Canymed") to supply the German market with medical cannabis. This move is the first of a series of strategic initiatives to penetrate the robust European cannabis market and marks the Company's expansion into its third continent alongside both North and South America.
https://mma.prnewswire.com/media/775962/Beleave_Inc__Beleave_Penetrates_European_Cannabis_Market_through.jpg
"Medical cannabis has been legal in Germany since March 2017 and the country has quickly become one of the world's largest federally-regulated medical cannabis markets. Its growth continues to outpace other jurisdictions with similar regulations and was a natural target as we expand our distribution channel into Europe," commented Beleave CEO, Andrew Wnek.
Key Takeaways of Agreement
-- Canymed to import 5,000 kg dry flower / year from Beleave;
-- Canymed to pay EUR 7.00 / gram to Beleave; and
-- Beleave will receive 10% ownership in Canymed and first right of refusal to purchase an additional 20% in exchange for providing its expertise, training, consultation and support.